Is Medicamen Biotec overvalued or undervalued?

Aug 31 2025 08:06 AM IST
share
Share Via
As of August 29, 2025, Medicamen Biotec is fairly valued with a PE ratio of 49.17, despite a 32.51% year-to-date decline, which is significantly higher than peers like Cipla and Dr. Reddy's Labs, indicating cautious optimism for future growth.
As of 29 August 2025, the valuation grade for Medicamen Biotec has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 49.17, an EV to EBITDA of 33.02, and a PEG ratio of 2.43.

In comparison to its peers, Medicamen Biotec's PE ratio is significantly higher than that of Cipla, which stands at 23.82, and Dr. Reddy's Labs, which has a PE of 18.56, indicating that while it is fairly valued, it remains on the higher end of the spectrum within the industry. The recent stock performance shows a decline of 32.51% year-to-date, contrasting with a 2.14% gain in the Sensex, further emphasizing the need for cautious optimism regarding future growth potential.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News